2021 ISPE Biotechnology Conference & Workshop

Now a Virtual Experience: 2021 ISPE Biotechnology Conference

As the COVID-19 pandemic continues to have an unforeseeable global impact, ISPE must constantly evaluate the delivery of our professional development opportunities to keep knowledge thriving while ensuring the safety of our community.

In that regard, we will transform the 2021 ISPE Biotechnology Conference and Workshop to be a fully digital experience.

Delegates will still benefit from robust, content-rich, interactive sessions covering critical topics like continuous manufacturing for mABs, research and development challenges for cell and gene therapies, Pharma 4.0™ in biotechnology, vaccine development, and more.

It is our priority to make this the best and most informative ISPE Biotechnology Conference to date, and we remain excited to host you in September in a virtual format that allows us to better reach our global Membership. We will update the event page in the coming weeks with additional information.

Special ISPE Industry Member Offer

Register by 27 August and receive €100 off the Live or Live + On Demand registration rate AND receive on demand access to the Regulatory Panel Discussion from the 2020 ISPE Europe Annual Conference for 30 days

Overview

The 2021 ISPE Biotechnology Virtual Conference & Workshop will bring together leading pharmaceutical and biopharmaceutical manufacturers, technology providers, academic scientists and international regulators to network, share insights and provide an outlook on the evolving landscape and future of Biopharmaceutical manufacturing and therapies. This year in particular the industry rallied together bring forward innovation at records and partnered in ways that were unprecedented to address not only the public health crisis brought on by the pandemic, but also to ensure patients worldwide would continue to have access to necessary therapies.

The conference will provide a leading interdisciplinary platform for all stakeholders of the pharmaceutical and biopharmaceutical value chain to present recent innovations and trends, and openly discuss practical challenges and solutions, from a technical, logistical and regulatory perspective. The impact of evolving regulatory environment, and the need to ensure continued innovation and continuity of the supply chain in light of this crisis and assuring preparedness for future crisis will be integrated throughout the conference programme, panel discussions, and accompanying workshops. Participant Participants will have the opportunity to engage with industry leaders, regulators and peers through networking events and conference programs.

Included in the key focus topics are:

  • Vaccines Development, Manufacturing, Distribution –accelerated development and approval
  • Research and Development challenges for Cell and Gene Therapy, Data and Process Science
  • Technology Transfer and Operations Readiness, Case studies
  • Manufacturing and Quality for Cell and Gene Therapy Products and ATMP
  • Continuous Manufacturing for mABs, Technology Enablers, Rationalisation
  • Pharma 4.0 in Biotechnology, Robotics, Digitalisation and Validation

Workshop

The programme also offers an interactive workshop, where the presentations of business cases and implemented projects will be discussed.

Objectives

  • How to prepare successful Biopharmaceutical Operations
  • How to unlock opportunities given by Digitisation
  • Learn from Covid-19 challenges

Why Attend Virtually

  • Feel like You're In-Person with a Fully Interactive Digital Experience
    Our event portal is easy to navigate and will allow you to view presentations, access PDFs of the presentations, take downloadable notes in each session, participate in polls, chat with other attendees, and participate in LIVE Q&A sessions with speakers.
    alt 1
  • Build Your Experience
    Add the sessions you want to attend with the click of a button to build your own custom agenda.
    alt 2
  • Gain Actionable Insights
    Global experts will be at your fingertips sharing their knowledge and lessons learned on advanced therapeutic medicinal products (ATMPs) including cell and gene therapies, digitalization, single-use technology, implications of ICH Q12 for biopharma, and much more.
    alt 3

Virtual Event FAQs


Who Should Attend

  • Professionals at all levels of the industry from young professionals to the most senior executives
  • Developers, Manufacturing and Engineering professionals involved in or interested in understanding the current state of biopharmaceutical production
  • Suppliers
  • Quality Assurance and Regulatory professionals
  • Process and Project Engineers
  • Regulators
  • Academia
  • Stakeholders of the Vaccination value chain

Media Partners

IPQ media partner
The Medicine Maker media partner

Receive Notifications

Stay up-to-date on registration, education opportunities, speakers, hotel discounts, exhibitor information, and more by signing up to receive notifications for the 2021 ISPE Biotechnology Conference

Name
Company Type

Programme Committee

Michelangelo Canzoneri
Global Head of Digital and Data, Healthcare
Merck KGaA, Darmstadt, Germany
Chair
David Doleski
Compliance Head for Biologics Quality Operations
Sanofi
Chair
Vivianne J. Arencibia
Independent Consultant
Arencibia Quality Compliance Associates
Placeholder Person Graphic
Angelo Bernardis
Mgr. of Pharma Process Design
Foster Wheeler Italiana Srl
Placeholder Person Graphic
Estelle Darnon
Expert Pharma / Process Architect
TechnipFMC
Richard Denk
Senior Consultant Aseptic Processing & Containment
SKAN AG
Liz M. Dooley, MSc.
Head of Biologics Clinical Planning & Operations, Janssen R&D
Janssen Sciences Ireland UC
Robert Dream, PE, CPIP
Principal
HDR Company LLC
David Estapé, PhD
Technology Manager Biotechnology
CRB Group
Joseph C. Famulare
Vice President, Global Quality Compliance and External Relations
Genentech, A Member of the Roche Group
Philip M. Gammell
Associate Director Engineering
Astellas Pharma Inc.
Christoph Herwig, PhD
Professor
Vienna University of Technology
Placeholder Person Graphic
Weining Hu
Distinguished Scientist/Executive Director
Merck
Antonio R. Moreira, PhD
Vice Provost, Academic Affairs
University of Maryland, Baltimore County
Placeholder Person Graphic
Gary O'Brien
Director, Business Development
DPS Group Global
Alice Redmond, PhD
Chief Strategy Officer
CAI
Phillip R. Smith, PhD
Director, Process Technology
GlaxoSmithKline
Christian Wölbeling
Executive Industry Advisor
Körber
Thomas Zahel, PhD
Head of Innovation
Körber Pharma, Werum IT Solutions GmbH